NCT04427293View on ClinicalTrials.gov

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Lenvatinib

Lenvatinib 12mg daily for 7 days prior to surgery

DRUG

Pembrolizumab

Pembrolizumab 200 mg IV on day 1

Trial Locations (1)

60612

RECRUITING

University of Illinois, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER